France’s INSERM Proposes Joint US–EU Medical Cannabis Clinical Data Study Following U.S. Rescheduling to Schedule III
The French National Institute of Health and Medical Research (INSERM) has proposed a collaborative study to analyze clinical data on medical cannabis from the United States and the European Union following the U.S. decision to reschedule to Schedule III. The move is expected to catalyze expanded transatlantic research cooperation.
For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.
Source
theconversation.com
This content is a summary and editorial by CannabisInsight based on the above source. Copyright of the original article belongs to the respective publisher.
Original Link
https://theconversation.com/reclassification-of-marijuana-opens-doors-for-much-needed-medical-research-into-the-benefits-and-risks-of-the-drug-281403